

DOCKET NO.: B0801.70195US00 1/FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Diego H. Castrillon
Serial No.: 09/714,865
Confirmation No.: 4880
Filed: November 16, 2000
For: COMPOSITIONS AND METHODS FOR THE IMPROVED
DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
Examiner: Karen A. Canella
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP Certificate of Correction, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 13th day of April, 2005.


Melissa L. Barlow Lyons

MAIL STOP Certificate of Correction

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE

OF CORRECTION UNDER 37 C.F.R. §1.322

Sir/Madam:

Patentees respectfully request the correction of an error found in the printing of the above-captioned patent. The correction made to claim 2 rectifies the typographical error made by the Patent Office.

Patentees point out that the correction requested does not involve a change in the patent that constitutes new matter or would require reexamination, and therefore, respectfully request that a certificate of correction be issued. Patentees encloses a copy of the patent page with the error highlighted. Since the errors were made by the Patent Office, it is respectfully submitted that no fee is due. However, if the examiner deems a fee necessary, the fee may be charged to the account of the undersigned, Deposit Account No. 23/2825. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

Respectfully submitted,
Diego H. Castrillon, Applicant

By:



MaryDilys S. Anderson, Ph.D., Reg. No.: 52,560
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: B0801.70195US00

Date: April 13, 2005

xNDDx

887411.1



DOCKET NO.: B0801.70195US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Diego H. Castrillon
Serial No.: 09/714,865
Confirmation No.: 4880
Filed: November 16, 2000
For: COMPOSITIONS AND METHODS FOR THE IMPROVED
DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
Examiner: Karen A. Canella
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP Certificate of Correction, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 13th day of April, 2005.


Melissa L. Barlow Lyons

MAIL STOP Certificate of Correction

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:


- Request for Certificate of Correction Under 37 C.F.R. § 1.322
- Certificate of Correction - Form PTO-1050
- Copy of pertinent page from U.S. Patent No. US 6,875,854 B1
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Diego H. Castrillon, Applicant

By:


MaryDilys S. Anderson, Ph.D., Reg. No.: 52,560
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: B0801.70195US00

Date: April 13, 2005

xNDDx

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : US 6,875,854 B1

DATE : April 5, 2005

INVENTORS : Diego H. Castrillon

It is certified that the error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 2, line 3 should read as shown below.

--sequence set forth as SEQ ID NO: 1.--

MAILING ADDRESS OF SENDER:

MaryDilys S. Anderson
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211

PATENT NO. US 6,875,854 B1



-continued

OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 46

| | |
|---|-----|
| ttttgcaaat acttgggttt agatgaagct gatcgatgt tggatatggg gtttggcct | 60 |
| cagattcgta gaatagtgcga acaagatact atgcctccaa aggggtgtccg ccacactatg | 120 |
| atgttagtgc tctatccaa taaggaaata cagatgtgg ctctgtattt cttaggatga | 180 |
| atatacttc ttgggtgtta gggaaaggagt tgggtctac ctctggaaaa catcacacag | 240 |
| gaaagtagtt ggggtggaa ggantcagga caaacgggtc atttctggct tgaccctccc | 300 |
| taaatggcaa cagggcaag ggatttcaact tgaccnttag gtgtttgtg ggggagaccc | 360 |
| caaaagggggg tgccaggnntt c | 381 |

<210> SEQ ID NO 47

<211> LENGTH: 361

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47

| | |
|---|-----|
| ttttgcaaat acttgggttt agatgaagct gatcgatgt tggatatggg gtttggcct | 60 |
| cagattcgta gaatagtgcga acaagatact atgcctccaa aggggtgtccg ccacactatg | 120 |
| atgttagtgc tctatccaa taaggaaata cagatgtgg ctctgtattt cttaggatga | 180 |
| tatatacttc ttgggtgttag ggaagagttt gctctaccc tcgaaacatc acaacagaaag | 240 |
| tagttgggtt gggaaaggaaat cagacaaacg gtcatttctg gcttggaccc cctaaatggc | 300 |
| aacaggggcaa gggttcaactt gaccttagt ttttgggg agacccaaaa aggggtgcca | 360 |
| g | 361 |

We claim:

1. An isolated nucleic acid molecule selected from the group consisting of:

(a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleotide sequence set forth as SEQ ID NO:1 and which code for a human vasa polypeptide, wherein the stringent conditions are: (1) hybridization at 65° C. in hybridization buffer (3.5×SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5 mM NaH₂PO₄(pH7), 0.5% SDS, 2 mM EDTA), wherein SSC is 0.15 M sodium chloride/0.015 M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetraacetic acid, and (2) washing in 2×SSC at room temperature and washing in 0.1×SSC/0.1 SDS at 68° C.,

(b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, or

(c) full-length complements of (a) or (b).

2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ NO: 1)

3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule consists of the nucleotide sequence set forth as SEQ ID NO:15.

4. A kit comprising a package containing an isolated nucleic acid molecule of claim 1.

* * * * *